The ascension of clinical organ transplantation by Starzl, TE
ELSEVIER 
The Ascension of Clinical Organ Transplantation 
T.E. Starzl 
D URING 1958 and 1959 at Northwestern Universitv (Chicago). we developed transplantation of the ca-
nine liver alone. I parallel to similar independent investiga-
tions in Boston hy Francis Moore.:'" The liver also was 
transplanted as a component of abdominal multivisceral 
grafts. 4 At the beginning. these were technical and physio-
logic exercises. because long-term survival of an organ 
allograft had never been achieved in any species. 
The possibility of clinically exploiting transplantation 
brightened. however. between January 1959 and the date of 
our first human liver replacement in March 1963. During 
this 4-year period. Joseph Murray in Boston5- 7 and the 
French teams of Jean HamburgerH and Rene Kuss" pro-
duced the 7 examples shown in Table 1 of survival exceed-
ing 6 months following human kidney transplantation. All 
of the patients except the last one had received total body 
irradiation, and in addition, 4 of the 5 French patients were 
treated with unstipulated doses of adrenal cortical steroids 
(Table 1) whose weak anti rejection effect had been dem-
onstrated by Billingham. Krohn. and Medawar lO in a rabbit 
skin graft model. The seventh recipient was treated with the 
6-mercaptopurine derivative (6-MP). azathioprine. Bob 
Schwartz's gift to transplantation. II .12 
It had been recognized during 1959 to 1962 that total 
hody irradiation would permit successful renal transplanta-
tion in only a small percent of cases. Consequently. the 
option of immunosuppression with 6-MP or its derivative, 
azathioprine was greeted initially with feverish enthusiasm. 
However. the preclinical studies of the new drugs by 
Table 1. Kidney Transplantation; 2:6 Months Survival as of 
March 1963 
Survival 
Case CityfoD~ Date Donor (months)! 
Boston5 1-24-59 Frat twin >50 
2 Paris· 6-29-59 Frat twin >45 
3 Paris9 6-22-60 Unrelated' 18(died) 
4 Pans· 12-19-60 Mother' 12(died) 
5 Paris9 3-12-61 Unrelated' 18(died) 
6 Paris· 2-12-62 Cousin' >13 
7 Boston6.7 4-5-62 Unrelated 10 
• Adlunct sterOid therapy. 
'The kidneys In patients 1. 2. and 6 functioned for 20.5. 25. and 15 years. 
respectively. Patient 7 rejected hiS graft after 17 months and died after retum to 
dialYSIS. 
Boston: J.E. Murray (1 and 7). 
Pans: J. Hamburger (2. 4. and 6); R. Kuss (3 and 5). 
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Calne1P·f~ and Zukoski.15 as well as Murray's human tri-
aI5,-7 cautioned that the clinical results might not he 
substantially better than with irradiation. even when aza-
thioprine was combined with other cytotoxic agents. The 
seventh patient in Table 1 was the only recipient of the first 
10 treated in Boston with 6-MP (n = 2) or azathioprine 
(n = 8) whose kidney allograft eventually survived more 
than 6 months. 
At the nadir of the resulting pessimism. we made our 
most important contribution to transplantation. 16 Realizing 
that clinical liver transplantation could never he attempted 
without first succeeding with the simpler renal procedure. 
we had turned our laboratory research to the canine kidney 
transplant model at the University of Colorado (where I 
had moved in November. 1961). Two reproducible obser-
vations were made. first in the mongrel dogs, and then in 
humans, that came to dominate future developments in 
organ transplantation. 
First, rejection. which had been considered to be one of 
nature's strongest and most irrevocable reaction. could he 
readily reversed hy adding high doses of prednisone to 
recipients under primary immunosuppression with azathio-
prine. Second. successfully treated recipients appeared to 
develop donor specific tolerance. This was manifested by 
the ability later on to wean the doses of drugs to levels 
below those which had failed at the outset to prevent the 
onset of rejection. 
Using azathioprine plus dose maneuverable prednisone. 
we began our clinical kidney transplant service in the 
autumn of 1962 at about the same time as David Hume. 
who was informed on a day to day hasis of our research and 
clinical findings. initiated his program at the Medical Col-
lege of Virginia (Richmond)n Nine of the first 10 recipi-
ents of live donor kidney allografts had prolonged graft 
survival. 16 including two who bear the longest continuously 
functioning allografts in the world today (>35.5 years). The 
two longest surviving patients have heen off of all immuno-
suppression for 32 and 4 years. 
This was the first series of successful clinical kidney 
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transplantations to he compiled in any center. At the time. 
the only programs in the United States where this proce-
dure was heing offered tll patients were in Richmond 
(David Hume) and in Boston at the Peter Bent Brigham 
Hospital (Joseph Murray). An earlier program directed hv 
Willard Goodwin at UCLA had heen closed because of 
poor results. hut not hefore making a signiticant contrihu-
tion. In September. IlJ60. Goodwin had produced profound 
hone marrow suppression with methotrexate and cyclo-
phosphamide (rather than with Irradiation) in the daughter 
recipient of a maternal kidney. During the 143 days of her 
survival. the patient developed severe rejections that were 
temporarily reversed with prednisone. This was the tirst 
example of protracted function of a human allograft using 
drug treatment only. but the case was not reported until 
1963 1H and was unknown during accrual of the Colorado 
series. 
In Europe. total hody irradiation remained the preferred 
treatment at the long-standing Paris centers of Jean Ham-
hurger and Rene Kuss. while Michael Woodruff of Edin-
hurgh had begun testing azathioprine. I" Within 12 months 
after the effectiveness of the double drug treatment became 
known, a proliferation occurred of new kidney transplant 
centers in North America. and also in Europe. 
The early kidney experience triggered our attempts be-
ginning in March of 1963 to replace the liver. the first 
extrarenal organ to be transplanted in humans. After the 
first three reported patients. ~EF two more in Boston and 
Paris, and an additional two in Denver all died within 23 
posttransplant days. clinical liver transplantation ceased 
worldwide. During the 3- 1/:! year moratorium. we developed 
antilymphocyte globulin (ALG) and tested it for the first 
time in kidney recipients. combined with azathioprine and 
prednisoneY 
When the triple drug immunosuppression proved en-
couraging in the kidney trial. the Colorado liver program 
was restarted in July 1967. A number of long survivals were 
obtainedI:~ including the three children shown in Figure I 
with their doctor. Carl Groth from the Karolinska Institute. 
then an NIH fellow in Denver. and now the President elect 
of the Transplantation Society. Another child from that 
early era whose operation was in January, 1970. is the 
longest surviving liver recipient in the world, married and in 
perfect health today. 
The successful liver transplantations in the summer of 
1967 expanded the horizon of transplantation from the 
kidney to all of the vital extrarenal organs. Within the 
succeeding 12 months. long survival was accomplished in 
other centers using variations of the same immunosuppres-
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Fig 1. The first three long-surviving liver recipients shown in 
Denver in the summer of 1967 with Carl Groth. president-elect in 
1998 of the Transplantation Society. 
sion for heart, lung, and pancreas recipients. Another 
decade would pass, however. before the advent of cyc1ospo-
rineOPK~4 would make transplantation of the liver25 or other 
cadaver organs a reliahle service. Tacrolimus. the first 
immunosuppressant to be evaluated primarily with liver 
transplantation.2" has allowed further improved survival of 
all transplanted organs induding the intestine. 
In later years. the management strategy originally devel-
oped with azathioprine and prednisone (Table 2) accom-
modated more potent haseline drugs as these came along 
(i.e., cydosporine and tacrolimus in place of azathioprine) 
and adjunct agents (e.g .. ALG and increasingly selective 
antilymphoid antibody preparations, mycophenolate 
mofetil. and other second line drugs). Despite the failure to 
understand what was being accomplished, the easily taught 
Table 2. Central Therapeutic Dogma of Immunosuppression 
Strategy 
1. Baseline therapy with one or two drugs 
2. Secondary adjustments With sterOids or antllymphold agents 
3. Case to case trial (and potential error) of weaning 
'Equivalent results With cyclOPhosphamIde. 
Baselme Agents 
Azathiopnne" 
Cyclosponne 
Tacrolimus 
Sites of Inhibition 
DNA syntheSIS 
Interleukin-2 production 
Interleukin-2 production 
y~ 
4< .. 
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ASCENSION OF TRANSPLANTATION 
algorithm became the base upon which clinical transplan-
tation of all organs was developed. 
The treatment regimens were shown ~ decades later to 
have been effective hecause they fostered chimerism-depen-
dent tolerance mechanisms2-:'.2s which were the same as in 
the neonatal models of Billingham. Brent. and Medawar?" 
The liver. which is more toler~genic than other organs.30.31 
ullimately became the key organ in solving the immunologic 
mystery of allograft acceptance and acquired tolerance.27.2H 
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